Systematic review: antibodies and anti‐TNF‐α levels in inflammatory bowel disease

The associations between clinical efficacy and infusion reactions with anti‐TNF‐α drug levels and the presence of antibodies against the drug have been described. However, the clinical utility of these tests in routine clinical practice remains unclear.

[1]  G. Paintaud,et al.  P334 Concentration effect relationship of infliximab in Crohn's disease: Results of a cohort study , 2012 .

[2]  M. Lukáš,et al.  P360 Infliximab trough levels may predict sustained response to infliximab in patients with Crohn's disease: A single cohort study , 2012 .

[3]  Ann Gils,et al.  OP11 Individualised infliximab treatment using therapeutic drug monitoring: A prospective controlled Trough level Adapted infliXImab Treatment (TAXIT) trial , 2012 .

[4]  P. Rutgeerts,et al.  OP10 Importance of trough levels and antibodies on the long-term efficacy of infliximab therapy in ulcerative colitis , 2012 .

[5]  G. D'Haens,et al.  Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis. , 2012, Gastroenterology.

[6]  A. Nesbitt,et al.  A PEGylated Fab’ Fragment against Tumor Necrosis Factor for the Treatment of Crohn Disease , 2012, BioDrugs.

[7]  P. Rutgeerts,et al.  Infliximab for Severe IV Steroid-Refractory Ulcerative Colitis: Can Infliximab Trough Levels Guide Our Management? , 2011 .

[8]  K. Bendtzen,et al.  Can Measurements of Anti-Infliximab Antibodies Predict Acute Severe Infusion Reactions to Infliximab? , 2011 .

[9]  Yasuo Suzuki,et al.  Monitoring functional serum antitumor necrosis factor antibody level in Crohn's disease patients who maintained and those who lost response to anti‐TNF , 2010, Inflammatory bowel diseases.

[10]  M. Gazouli,et al.  Report of the ECCO workshop on anti-TNF therapy failures in inflammatory bowel diseases: biological roles and effects of TNF and TNF antagonists. , 2010, Journal of Crohn's & colitis.

[11]  R. Fedorak,et al.  Tumor necrosis factor-α monoclonal antibodies in the treatment of inflammatory bowel disease: clinical practice pharmacology. , 2010, Gastroenterology clinics of North America.

[12]  S. Brand,et al.  Disease Activity, ANCA, and IL23R Genotype Status Determine Early Response to Infliximab in Patients With Ulcerative Colitis , 2010, The American Journal of Gastroenterology.

[13]  U. Kopylov,et al.  The immunogenic part of infliximab is the F(ab′)2, but measuring antibodies to the intact infliximab molecule is more clinically useful , 2010, Gut.

[14]  W. Sandborn,et al.  Clinical Utility of Measuring Infliximab and Human Anti-Chimeric Antibody Concentrations in Patients With Inflammatory Bowel Disease , 2010, The American Journal of Gastroenterology.

[15]  A. Cohen,et al.  S1051 Methotrexate for the Prevention of Antibodies to Infliximab in Patients With Crohn's Disease , 2010 .

[16]  P. Rutgeerts,et al.  405 High Infliximab Trough Levels are Associated With Mucosal Healing in Crohn's Disease , 2010 .

[17]  Y. Chiu,et al.  741 Evaluation of Potential Correlations Between Serum Adalimumab Concentration and Remission in Patients With Crohn's Disease in Classic I and II , 2010 .

[18]  P. Rutgeerts,et al.  Infliximab, azathioprine, or combination therapy for Crohn's disease. , 2010, The New England journal of medicine.

[19]  E. Bonfá,et al.  Immunogenicity of Anti-TNF-α Agents in Autoimmune Diseases , 2010, Clinical reviews in allergy & immunology.

[20]  B. Dijkmans,et al.  Relationship between the clinical response to adalimumab treatment and serum levels of adalimumab and anti-adalimumab antibodies in patients with psoriatic arthritis , 2010, Annals of the rheumatic diseases.

[21]  Takahiko Horiuchi,et al.  Transmembrane TNF-α: structure, function and interaction with anti-TNF agents , 2010, Rheumatology.

[22]  B. Dijkmans,et al.  Anti-infliximab and anti-adalimumab antibodies in relation to response to adalimumab in infliximab switchers and anti-tumour necrosis factor naive patients: a cohort study , 2009, Annals of the rheumatic diseases.

[23]  P. Rutgeerts,et al.  The effect of dose escalation on trough levels in patients who lost response to infliximab , 2010 .

[24]  P. Rutgeerts,et al.  Influence of trough serum levels and immunogenicity on long-term outcome of adalimumab therapy in Crohn's disease. , 2009, Gastroenterology.

[25]  M. Silverberg,et al.  Trough serum infliximab: a predictive factor of clinical outcome for infliximab treatment in acute ulcerative colitis , 2009, Gut.

[26]  S. Travis,et al.  Incidence and clinical significance of immunogenicity to infliximab in Crohn's disease: A critical systematic review , 2009, Inflammatory bowel diseases.

[27]  W. Sandborn,et al.  Clinical trial: benefits and risks of immunomodulators and maintenance infliximab for IBD‐subgroup analyses across four randomized trials , 2009, Alimentary pharmacology & therapeutics.

[28]  E. Sasso,et al.  Comparisons of affinities, avidities, and complement activation of adalimumab, infliximab, and etanercept in binding to soluble and membrane tumor necrosis factor. , 2009, Clinical immunology.

[29]  J. Gisbert,et al.  Loss of Response and Requirement of Infliximab Dose Intensification in Crohn's Disease: A Review , 2009, The American Journal of Gastroenterology.

[30]  K. Bendtzen,et al.  Individual medicine in inflammatory bowel disease: Monitoring bioavailability, pharmacokinetics and immunogenicity of anti-tumour necrosis factor-alpha antibodies , 2009, Scandinavian journal of gastroenterology.

[31]  E. Kuipers,et al.  Immunogenicity negatively influences the outcome of adalimumab treatment in Crohn’s disease , 2008, Alimentary pharmacology & therapeutics.

[32]  P. Rutgeerts,et al.  Withdrawal of immunosuppression in Crohn's disease treated with scheduled infliximab maintenance: a randomized trial. , 2008, Gastroenterology.

[33]  K. Bendtzen,et al.  Tumor Necrosis Factor-Alpha Binding Capacity and Anti-Infliximab Antibodies Measured by Fluid-Phase Radioimmunoassays as Predictors of Clinical Efficacy of Infliximab in Crohn's Disease , 2008, The American Journal of Gastroenterology.

[34]  G. D'Haens,et al.  Adalimumab Induction Therapy for Crohn Disease Previously Treated with Infliximab: A Randomized Trial , 2008 .

[35]  G. Kaplan,et al.  Infliximab dose escalation vs. initiation of adalimumab for loss of response in Crohn’s disease: a cost‐effectiveness analysis , 2007, Alimentary pharmacology & therapeutics.

[36]  S. Targan,et al.  Natalizumab for the treatment of active Crohn's disease: results of the ENCORE Trial. , 2007, Gastroenterology.

[37]  P. Rutgeerts,et al.  Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn’s disease , 2007, Gut.

[38]  S. Hanauer,et al.  General principles and pharmacology of biologics in inflammatory bowel disease. , 2006, Gastroenterology clinics of North America.

[39]  J. Gisbert,et al.  Monitorización de la tiopurina metiltransferasa y de los metabolitos tiopurínicos para optimizar el tratamiento con azatioprina en la enfermedad inflamatoria intestinal , 2006 .

[40]  M. Silverberg,et al.  Association of trough serum infliximab to clinical outcome after scheduled maintenance treatment for Crohn's disease. , 2006, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[41]  J. Mate,et al.  [Monitoring of thiopurine methyltransferase and thiopurine metabolites to optimize azathioprine therapy in inflammatory bowel disease]. , 2006, Gastroenterologia y hepatologia.

[42]  C. Aybay,et al.  Demonstration of specific antibodies against infliximab induced during treatment of a patient with ankylosing spondylitis , 2006, Rheumatology International.

[43]  S. Targan,et al.  Natalizumab induction and maintenance therapy for Crohn's disease. , 2005, The New England journal of medicine.

[44]  S. Schreiber,et al.  A randomized, placebo-controlled trial of certolizumab pegol (CDP870) for treatment of Crohn's disease. , 2005, Gastroenterology.

[45]  M. Bala,et al.  Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn's disease. , 2004, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[46]  P. Rutgeerts,et al.  Optimizing anti-TNF treatment in inflammatory bowel disease. , 2004, Gastroenterology.

[47]  M. Peppercorn,et al.  Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn's disease: a randomized controlled trial. , 2003, Gastroenterology.

[48]  An Carbonez,et al.  Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. , 2003, The New England journal of medicine.

[49]  S. Hanauer,et al.  For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group , 2022 .

[50]  S. Targan,et al.  Tumor necrosis factor: biology and therapeutic inhibitors. , 2000, Gastroenterology.

[51]  J. Bonnefoy,et al.  Human NK cells constitutively express membrane TNF‐α (mTNFα) and present mTNFα‐dependent cytotoxic activity , 1999 .

[52]  Y. Goltsev,et al.  Tumor necrosis factor receptor and Fas signaling mechanisms. , 1999, Annual review of immunology.

[53]  G. Kollias,et al.  Impaired on/off regulation of TNF biosynthesis in mice lacking TNF AU-rich elements: implications for joint and gut-associated immunopathologies. , 1999, Immunity.

[54]  J. Bonnefoy,et al.  Human NK cells constitutively express membrane TNF-alpha (mTNFalpha) and present mTNFalpha-dependent cytotoxic activity. , 1999, European journal of immunology.

[55]  J. Keane,et al.  Pathogenic Mycobacterium tuberculosis evades apoptosis of host macrophages by release of TNF-R2, resulting in inactivation of TNF-alpha. , 1998, Journal of immunology.

[56]  S. Targan,et al.  A Short-Term Study of Chimeric Monoclonal Antibody cA2 to Tumor Necrosis Factor α for Crohn's Disease , 1997 .

[57]  M. Feldmann,et al.  Contact with T cells modulates monocyte IL-10 production: role of T cell membrane TNF-alpha. , 1997, Journal of immunology.

[58]  Nicole Nelson,et al.  A metalloproteinase disintegrin that releases tumour-necrosis factor-α from cells , 1997, Nature.

[59]  S. Targan,et al.  A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. , 1997, The New England journal of medicine.

[60]  B. Castner,et al.  A metalloproteinase disintegrin that releases tumour-necrosis factor-alpha from cells. , 1997, Nature.

[61]  T. Decker,et al.  Cell-associated tumor necrosis factor (TNF) as a killing mechanism of activated cytotoxic macrophages. , 1987, Journal of immunology.